A feasibility study of preoperative pembrolizumab before radical nephroureterectomy in patients with high-risk, upper tract urothelial carcinoma: PURE-02
Andrea Necchi(Vita-Salute San Raffaele University), Francesco Montorsi(Vita-Salute San Raffaele University), Elio Mazzone(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Luca Villa(Vita-Salute San Raffaele University), Alessandro Larcher(IRCCS Ospedale San Raffaele), Francesco Barletta(Vita-Salute San Raffaele University), Alberto Briganti(University College London Hospitals NHS Foundation Trust), Alberto Martini(The University of Texas MD Anderson Cancer Center), Roberta Lucianò(Vita-Salute San Raffaele University), Umberto Capitanio(Vita-Salute San Raffaele University), Andrea Salonia(Vita-Salute San Raffaele University), A. Messina(Fondazione IRCCS Istituto Nazionale dei Tumori), Vito Cucchiara(IRCCS Ospedale San Raffaele), Daniele Raggi(Fondazione IRCCS Istituto Nazionale dei Tumori), Simone Scuderi(University of Catania), Marco Bandini(IRCCS Ospedale San Raffaele), Maurizio Colecchia, Giuseppe Basile(Vita-Salute San Raffaele University), Jeffrey S. Ross(Unknown), Filippo Pederzoli(Cornell University)
Cited by 42
Related Papers
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
|The Lancet Oncology|2017|1.8k
Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study
|Nature Medicine|2019|726